News
MHRA marketing authorisation granted for Eli Lilly’s Verzenios as early breast cancer treatment
Eli Lilly’s Verzenios (abemaciclib) has received a marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA), in combination with endocrine therapy for the adjuvant treatment of patients with HR+, HER2-, high risk node-positive early breast cancer (EBC).